Compounds > aminolevulinic acid
Page last updated: 2024-10-16

aminolevulinic acid and Abdominal Pain

aminolevulinic acid has been researched along with Abdominal Pain in 10 studies

Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.
5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.

Abdominal Pain: Sensation of discomfort, distress, or agony in the abdominal region.

Research Excerpts

ExcerptRelevanceReference
"Attacks of neuropathic pain, usually abdominal, are characteristic of the acute porphyrias and accompanied by overproduction of heme-precursor molecules, specifically delta-aminolevulinic acid and porphobilinogen."7.81Role of delta-aminolevulinic acid in the symptoms of acute porphyria. ( Bissell, DM; Blanc, PD; Lai, JC; Meister, RK, 2015)
"There is now convincing evidence that delta-aminolevulinic acid is the cause of pain in the acute porphyrias."7.81Role of delta-aminolevulinic acid in the symptoms of acute porphyria. ( Bissell, DM; Blanc, PD; Lai, JC; Meister, RK, 2015)
"Attacks of neuropathic pain, usually abdominal, are characteristic of the acute porphyrias and accompanied by overproduction of heme-precursor molecules, specifically delta-aminolevulinic acid and porphobilinogen."5.42Role of delta-aminolevulinic acid in the symptoms of acute porphyria. ( Bissell, DM; Blanc, PD; Lai, JC; Meister, RK, 2015)
"We review genetic acute porphyria, hereditary tyrosinemia, and an acquired condition, lead poisoning."5.42Role of delta-aminolevulinic acid in the symptoms of acute porphyria. ( Bissell, DM; Blanc, PD; Lai, JC; Meister, RK, 2015)
"The acute hepatic porphyrias (AHP) are rare, inborn errors of heme-metabolism and include acute intermittent porphyria, hereditary coproporphyria, variegate porphyria, and porphyria due to severe deficiency of 5-aminolevulinic acid dehydratase."5.41AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review. ( Balwani, M; Bonkovsky, HL; Lim, JK; Wang, B, 2023)
"Attacks of neuropathic pain, usually abdominal, are characteristic of the acute porphyrias and accompanied by overproduction of heme-precursor molecules, specifically delta-aminolevulinic acid and porphobilinogen."3.81Role of delta-aminolevulinic acid in the symptoms of acute porphyria. ( Bissell, DM; Blanc, PD; Lai, JC; Meister, RK, 2015)
"There is now convincing evidence that delta-aminolevulinic acid is the cause of pain in the acute porphyrias."3.81Role of delta-aminolevulinic acid in the symptoms of acute porphyria. ( Bissell, DM; Blanc, PD; Lai, JC; Meister, RK, 2015)
"Acute intermittent porphyria is the most common type of AHP, with an estimated prevalence of patients with symptoms of approximately 1 in 100,000."3.01AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review. ( Balwani, M; Bonkovsky, HL; Lim, JK; Wang, B, 2023)
"The acute hepatic porphyrias (AHP) are rare, inborn errors of heme-metabolism and include acute intermittent porphyria, hereditary coproporphyria, variegate porphyria, and porphyria due to severe deficiency of 5-aminolevulinic acid dehydratase."3.01AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review. ( Balwani, M; Bonkovsky, HL; Lim, JK; Wang, B, 2023)
"Type 2 diabetes mellitus is prevalent especially in Gulf countries and poses serious long-term risks to patients."2.82The Safety and Tolerability of 5-Aminolevulinic Acid Phosphate with Sodium Ferrous Citrate in Patients with Type 2 Diabetes Mellitus in Bahrain. ( Al-Saber, F; Aldosari, W; Alselaiti, M; Darwish, A; Harb, G; Kaladari, A; Khalfan, H; Khan, G; Koda, A; Kudo, S; Nakajima, M; Rehani, R; Tanaka, T, 2016)
"Attacks of neuropathic pain, usually abdominal, are characteristic of the acute porphyrias and accompanied by overproduction of heme-precursor molecules, specifically delta-aminolevulinic acid and porphobilinogen."1.42Role of delta-aminolevulinic acid in the symptoms of acute porphyria. ( Bissell, DM; Blanc, PD; Lai, JC; Meister, RK, 2015)
"We review genetic acute porphyria, hereditary tyrosinemia, and an acquired condition, lead poisoning."1.42Role of delta-aminolevulinic acid in the symptoms of acute porphyria. ( Bissell, DM; Blanc, PD; Lai, JC; Meister, RK, 2015)

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (10.00)18.2507
2000's4 (40.00)29.6817
2010's4 (40.00)24.3611
2020's1 (10.00)2.80

Authors

AuthorsStudies
Wang, B1
Bonkovsky, HL1
Lim, JK1
Balwani, M1
Bissell, DM1
Lai, JC1
Meister, RK1
Blanc, PD1
Al-Saber, F1
Aldosari, W1
Alselaiti, M1
Khalfan, H1
Kaladari, A1
Khan, G1
Harb, G1
Rehani, R1
Kudo, S1
Koda, A1
Tanaka, T1
Nakajima, M1
Darwish, A1
Tébar, MT1
Aguilera, L1
Bouizegarene, P1
Puy, H1
da Silva, VP1
Deybach, JC1
López Montes, A1
Lorenzo, I1
Pérez Martínez, J1
Doss, MO1
Stauch, T1
Gross, U1
Renz, M1
Akagi, R1
Doss-Frank, M1
Seelig, HP1
Sassa, S1
Herrick, AL1
McColl, KE1
Bloomer, JR1
McGuire, BM1
Schattenberg, AV1
de Pauw, BE1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Pilot Study to Evaluate the Safety and Efficacy of 5-ALA-SFC in Subjects With Type II Diabetes[NCT02481141]53 participants (Actual)Interventional2014-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in 2 Hour Post Meal Glucose Level

Change from baseline in blood glucose levels 2 hours after breakfast (NCT02481141)
Timeframe: Baseline, Week 2, Week 4, Week 12

Interventionmg/dL (Mean)
5-ALA-SFC Through Week 2 (50 mg 2x/Day) Change From Baseline-0.2
5-ALA-SFC Through Week 4 (75 mg 2x/Day) Change From Baseline-12.9
5-ALA-SFC Through Week 12 (100 mg 2x/Day) Change From Baseline-8.5
Placebo Through Week 2 Change From Baseline-26.5
Placebo Through Week 4 Change From Baseline-18.8
Placebo Through Week 12 Change From Baseline-33.0

Change From Baseline in Body Weight

Change from baseline measured at week 6 and week 12 only (NCT02481141)
Timeframe: Baseline, Week 6, Week 12

Interventionkg (Mean)
5-ALA-SFC Through Week 6 Change From Baseline-0.1
5-ALA-SFC Through Week 12 Change From Baseline-0.2
Placebo Through Week 6 Change From Baseline-0.3
Placebo Through Week 12 Change From Baseline-0.8

Change From Baseline in Fasting Blood Glucose

The objective of the current study was to investigate the safety and preliminary efficacy of doses up to 200 mg 5-ALA - SFC in a population of patients with type 2 diabetes mellitus living in Bahrain. (NCT02481141)
Timeframe: Baseline, Week 2, Week 4, Week 12

Interventionmg/dL (Mean)
5-ALA-SFC Through Week 2 (50 mg 2x/Day) Change From Baseline2.3
5-ALA-SFC Through Week 4 (75 mg 2x/Day) Change From Baseline-0.2
5-ALA-SFC Through Wk 12 (100 mg 2x/Day) Change From Baseline-3.0
Placebo Through Week 2 Change From Baseline-7.3
Placebo Through Week 4 Change From Baseline-0.8
Placebo Through Week 12 Change From Baseline-4.2

Change From Baseline in HbA1c

Change from baseline in HbA1c % (NCT02481141)
Timeframe: Baseline, Week 2, Week 4, Week 12

Interventionpercentage of HbA1c (Mean)
5-ALA-SFC Through Week 2 (50 mg 2x/Day) Change From Baseline-0.2
5-ALA-SFC Through 4 (75 mg 2x/Day) Change From Baseline-0.3
5-ALA-SFC Through 12 (100 mg 2x/Day) Change From Baseline-0.7
Placebo Through Week 2 Change From Baseline-0.5
Placebo Through Week 4 Change From Baseline-0.5
Placebo Through Week 12 Change From Baseline-0.5

Change From Baseline in HDL (Component of Lipid Profile)

Change from baseline measured at week 6 and week 12 only (NCT02481141)
Timeframe: Baseline, Week 6, Week 12

Interventionmg/dL (Mean)
5-ALA-SFC Through Week 6 Change From Baseline-0.8
5-ALA-SFC Through Week 12 Change From Baseline0.5
Placebo Through Week 6 Change From Baseline-1.6
Placebo Through Week 12 Change From Baseline-1.1

Change From Baseline in Total Cholesterol (Component of Lipid Profile)

Change from baseline measured at week 6 and week 12 only (NCT02481141)
Timeframe: Baseline, Week 6, Week 12

Interventionmg/dL (Mean)
5-ALA-SFC Through Week 6 Change From Baseline-5.2
5-ALA-SFC Through Week 12 Change From Baseline6.8
Placebo Through Week 6 Change From Baseline-7.6
Placebo Through Week 12 Change From Baseline-0.1

Change From Baseline in Triglycerides (Component of Lipid Profile)

Change from baseline measured at week 6 and week 12 only (NCT02481141)
Timeframe: Baseline, Week 6, Week 12

Interventionmg/dL (Mean)
5-ALA-SFC Through Week 6 Change From Baseline-1.3
5-ALA-SFC Through Week 12 Change From Baseline3.2
Placebo Through Week 6 Change From Baseline4.5
Placebo Through Week 12 Change From Baseline11.9

Change From Baseline LDL (Component of Lipid Profile)

Change from baseline measured at week 6 and week 12 only (NCT02481141)
Timeframe: Baseline, Week 6, Week 12

Interventionmg/dL (Mean)
5-ALA-SFC Through Week 6 Change From Baseline-2.9
5-ALA-SFC Through Week 12 Change From Baseline7.6
Placebo Through Week 6 Change From Baseline-11.8
Placebo Through Week 12 Change From Baseline-4.0

Subjects With Adverse Events as a Measure of Safety and Tolerability

The objective of the current study was to investigate the safety and preliminary efficacy of doses up to 200 mg 5-ALA - SFC in a population of patients with type 2 diabetes mellitus living in Bahrain. (NCT02481141)
Timeframe: Week 2, Week 4, Week 12

InterventionParticipants (Count of Participants)
5-ALA-SFC Through Week 2 (50 mg 2x/Day)6
5-ALA-SFC Through Week 4 (75 mg 2x/Day)8
5-ALA-SFC Through Week 12 (100 mg 2x/Day)2
Placebo Through Week 23
Placebo Through Week 41
Placebo Through Week 121

Reviews

3 reviews available for aminolevulinic acid and Abdominal Pain

ArticleYear
AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.
    Gastroenterology, 2023, Volume: 164, Issue:3

    Topics: Abdominal Pain; Aminolevulinic Acid; Antiemetics; Carcinoma, Hepatocellular; Creatinine; Female; Hem

2023
Acute intermittent porphyria.
    Best practice & research. Clinical gastroenterology, 2005, Volume: 19, Issue:2

    Topics: Abdominal Pain; Adult; Aminolevulinic Acid; Cytochrome P-450 Enzyme System; Erythrocytes; Female; He

2005
[Perplexing acute or chronic somatic or psychiatric symptoms: possibly due to porphyria].
    Nederlands tijdschrift voor geneeskunde, 1998, Aug-08, Volume: 142, Issue:32

    Topics: Abdominal Pain; Adult; Aminolevulinic Acid; Disease Management; Female; Humans; Laparotomy; Mental D

1998

Trials

1 trial available for aminolevulinic acid and Abdominal Pain

ArticleYear
The Safety and Tolerability of 5-Aminolevulinic Acid Phosphate with Sodium Ferrous Citrate in Patients with Type 2 Diabetes Mellitus in Bahrain.
    Journal of diabetes research, 2016, Volume: 2016

    Topics: Abdominal Pain; Aminolevulinic Acid; Bahrain; Blood Glucose; Citric Acid; Cough; Diabetes Mellitus,

2016

Other Studies

6 other studies available for aminolevulinic acid and Abdominal Pain

ArticleYear
Role of delta-aminolevulinic acid in the symptoms of acute porphyria.
    The American journal of medicine, 2015, Volume: 128, Issue:3

    Topics: Abdominal Pain; Adult; Aminolevulinic Acid; Chelation Therapy; Diagnosis, Differential; Female; Heme

2015
[Acute intermittent porphyria and inappropriate ADH syndrome].
    Revista espanola de anestesiologia y reanimacion, 2010, Volume: 57, Issue:5

    Topics: Abdominal Pain; Adult; Aminolevulinic Acid; Coproporphyrins; Delayed Diagnosis; Dietary Carbohydrate

2010
[Porphyria. What to think in the absence of a cause of abdominal pain].
    La Revue du praticien, 2010, Dec-20, Volume: 60, Issue:10

    Topics: Abdominal Pain; Aminolevulinic Acid; Female; Humans; Porphobilinogen; Porphyria, Acute Intermittent;

2010
[Porphyria and inappropriate antidiuretic hormone syndrome].
    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2004, Volume: 24 Suppl 3

    Topics: Abdominal Pain; Adult; Aminolevulinic Acid; Coproporphyrins; Diuretics; Endometriosis; Female; Furos

2004
The third case of Doss porphyria (delta-amino-levulinic acid dehydratase deficiency) in Germany.
    Journal of inherited metabolic disease, 2004, Volume: 27, Issue:4

    Topics: Abdominal Pain; Adolescent; Aminolevulinic Acid; Dithiothreitol; Erythrocytes; Germany; Humans; Male

2004
Intermittent unexplained abdominal pain: is it porphyria?
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2007, Volume: 5, Issue:11

    Topics: Abdominal Pain; Acute Disease; Adult; Aminolevulinic Acid; Anti-Infective Agents; Cimetidine; Contra

2007